Why Experts Are Sounding the Alarm Over the New Cicada COVID Variant Emerging After Two Years Underground

Just when the world had begun to breathe a collective sigh of relief, thinking that the era of unpredictable COVID variants was finally behind us, a startling new strain has surfaced, immediately capturing the attention of scientists, epidemiologists, and public health officials alike. Dubbed “Cicada” for its uncanny behavior, this variant—officially designated BA.3.2—is now being detected in dozens of countries, including at least 25 U.S. states, and has reignited debates over how prepared we really are for the virus’s next evolutionary gambit.

The nickname “Cicada” is more than a catchy label; it encapsulates the virus’s extraordinary pattern of stealth and delayed emergence. Much like the insect for which it is named—an organism that spends years hidden underground before suddenly swarming in massive numbers—BA.3.2 was first identified in South Africa in late 2024, yet for nearly two years, it remained almost invisible. Surveillance systems barely registered its presence as it circulated quietly at low levels, under the radar of global monitoring efforts. Then, in early 2026, reports began to surge across Europe and North America, showing the variant’s ability to “wake up” and spread rapidly, seemingly overnight, to regions that had assumed they were largely shielded by vaccination and prior infections.

Experts such as Dr. Andrew Pekosz of Johns Hopkins have expressed particular concern over the Cicada variant’s genetic composition. BA.3.2 harbors between 70 and 75 mutations in its spike protein alone—the portion of the virus responsible for binding to human cells—making it the most heavily mutated SARS-CoV-2 variant identified since the original Omicron wave. For comparison, the spike protein changes seen in the JN.1 and LP.8.1 variants, which shaped the design of the 2025–2026 vaccines, are far less extensive. The sheer number and combination of these mutations could explain why BA.3.2 appears almost unrecognizable to our immune defenses.

This “highly divergent” genetic profile has profound implications for immunity. Early laboratory tests conducted by the CDC and partner international labs indicate that antibodies from previous infections or from the latest booster doses are notably less effective at neutralizing the Cicada strain. In practical terms, this means that while someone previously infected or vaccinated may still have some protection, the variant is adept at slipping past these first-line defenses. Epidemiologists are already watching closely as BA.3.2 climbs in prevalence. In parts of Denmark and Germany, for example, it now accounts for roughly 30% of all sequenced cases, suggesting that it may be outcompeting other circulating variants due to its enhanced ability to infect even those with prior immunity.

Despite the attention it is receiving, the news is not uniformly alarming. At present, there is no evidence that Cicada causes more severe illness or increases mortality compared with other Omicron descendants. Reported symptoms largely resemble those associated with prior variants: a sharp, sore throat likened to a “razorblade,” fatigue, nasal congestion, and persistent cough. Some patients have described more frequent night sweats, though the loss of taste and smell—which defined earlier COVID waves—remains a rarity.

Importantly, vaccines continue to provide a vital shield. While their effectiveness in preventing infection from BA.3.2 may be reduced, their capacity to prevent severe outcomes—hospitalizations, ICU admissions, and death—remains robust. The body’s T-cell response, often overshadowed in public discussions by antibodies, continues to recognize enough viral components to offer strong protection against life-threatening disease. In short, even if the virus manages to infect, the immune system is still capable of keeping most cases manageable.

Monitoring trends in the United States is proving challenging. As of late March 2026, Cicada is still responsible for a relatively small proportion of confirmed cases. However, wastewater surveillance tells a more nuanced story: detections are occurring coast to coast, from Hawaii to New York, suggesting that the variant is spreading more rapidly than clinical testing alone would reveal. This discrepancy underscores the importance of multiple monitoring strategies and reminds public health officials that confirmed case counts are often just the tip of the iceberg.

What happens next depends on a combination of viral evolution and human response. Will BA.3.2 ignite a summer surge similar to previous waves, or will it continue circulating quietly, like a background whisper in the population? Epidemiologists emphasize that predicting the trajectory is challenging because the virus continues to evolve in real time, testing the resilience of both immunity and public health infrastructure.

For now, experts advocate a stance of “measured vigilance.” The Cicada variant has emerged, and although it does not appear to be a “killer” in the same sense as some previous waves, it serves as a stark reminder that SARS-CoV-2 is far from done with its evolutionary tricks. Its ability to hibernate, mutate extensively, and suddenly reemerge highlights a core reality of the pandemic era: the virus adapts, often in ways that challenge our assumptions and preparedness. The world may have entered a post-pandemic phase, but the emergence of BA.3.2 underscores that vigilance, scientific monitoring, and public health awareness remain essential tools in our ongoing effort to live with COVID-19 safely.